The combination of once-weekly cagrilintide 2.4 mg and semaglutide 2.4 mg conferred greater weight loss at 68 weeks compared ...

Patients who took a lower dose lost more weight on average. Read more at straitstimes.com. Read more at straitstimes.com.

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...

In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...

The U.S. trade deficit with Ireland has surged as $36 billion in hormone shipments for weight-loss and diabetes drugs were flown in to meet demand and avoid tariffs.

With semaglutide and tirzepatide dosed once weekly, their estimated average yearly costs in the U.S. are $14,080 and $8,126, respectively. What's more, obesity alone as an indication bars coverage ...

GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...

Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...